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Objective 
Anti-nuclear autoantibodies are known to occur in 85-99% of Systemic Sclerosis (SSc) 
patients, with each SSc autoantibody correlating with a distinct clinical subset of patients. 
The objective of this study was to investigate novel SSc autoantibodies in the remaining 
autoantibody negative patients and establish clinical associations. 
Methods 
Serum samples and clinical data were collected from 548 SSc patients. Sera were tested for 
known SSc autoantibodies by routine serological techniques, with negative samples being 
further investigated by radiolabelled protein immunoprecipitation (IPP). Sera that 
immunoprecipitated a novel 30 kDa band were analysed by indirect immunofluorescence 
and IPP using depleted cell extracts to establish a common reactivity. Mass spectrometry 
(MS) was used to identify the novel autoantigen and findings were confirmed using 
commercial antibodies. Sera from 426 patients with other forms of connective tissue 
disease, 103 patients with rheumatoid arthritis, 114 patients with idiopathic ILD and 150 
healthy controls were serotyped as controls. 
 
Results 
A novel autoantigen with a molecular weight of ~30 kDa was recognised by seven sera with 
SSc, six of whom had interstitial lung disease (ILD) and by no controls. Six of the patients had 
diffuse cutaneous involvement and four had overlap features with other autoimmune 
diseases. Immunodepletion experiments indicated that all samples targeted the same 
autoantigen and MS identified the novel autoantigen as eIF2B (Eukaryotic Initiation Factor 
2B).  
 
Conclusion 
We report a novel autoantibody (anti-eIF2B) in a small number of patients with SSc 
(approximately 1%) that is closely associated with diffuse cutaneous manifestations and the 
presence of ILD.  
 
Systemic Sclerosis (SSc) is an uncommon disease characterised by microvascular damage 
and fibrosis of the skin and internal organs (1), with anti-nuclear autoantibodies (ANA) 
occurring in 85-99% of patients (2). The most common autoantibodies are anti-centromere 
(ACA) found in 7-40% of patients and anti-topoisomerase-1 (ATA, also known as anti-Scl-70) 
found in 9-42% of patients. Other SSc-specific autoantibodies include anti-RNA-polymerase-
III, anti-U3-RNP/Fibrillarin, anti-Th/To and anti-U11/12. Additionally, SSc-associated 
autoantibodies such as; anti-Pm-Scl, anti-U1-RNP, anti-Ro/La  and anti-Ku  are found in SSc 
patients with overlapping autoimmune conditions including; Sjögren’s syndrome (SS), 
systemic lupus erythematosus (SLE) and myositis (2-4). Studies have demonstrated strong 
clinical associations between autoantibody class and disease phenotype (5) and whilst the 
SSc-specific autoantibodies are generally mutually exclusive, combinations of SSc-associated 
autoantibodies are more prevalent (2, 6). However, despite the identification of these 
autoantibodies, there still remains a group of SSc patients who appear to be autoantibody 
negative.  Herein we report a novel autoantibody to eIF2B (Eukaryotic Initiation Factor 2B) 
in seven SSc patients who are negative for published SSc-specific autoantibodies. 
Patients and Methods 
Patient Cohort 
Clinical data and sera were available from 548 SSc patients who fulfilled either the ARA 
and/or the LeRoy and Medsger criteria (7, 8). The study included 379 consecutive patients 
assessed for interstitial lung disease (ILD) at the Royal Brompton Hospital (RBH), mainly 
referred by the Royal Free Hospital. The remaining 169 patients attended the Royal National 
Hospital for Rheumatic Diseases (RNHRD). Clinical data were collected using standardised 
pro-formas and patients were classified as having either limited (lcSSc) or diffuse (dcSSc) 
cutaneous SSc according to LeRoy et al (8). The control population consisted of 211 patients 
with SLE, 42 patients with SS, 17 patients with SLE/SS overlap, 103 patients with rheumatoid 
arthritis (RA) (33 with ILD), 126 patients with myositis, 30 patients with undifferentiated 
connective tissue disease (UCTD) (defined by having symptoms suggestive of CTD but not 
fulfilling specific criteria), 114 patients with idiopathic ILD (defined by HRCT scan, or where 
not available, by the presence of bilateral basal inspiratory crackles on physical examination 
accompanied by reduced diffusing capacity on pulmonary function tests), and 150 healthy 
controls.  Written consent to participate and provide biological samples was obtained from 
all subjects according to the Declaration of Helsinki, under the local ethical committee 
regulations. 
 
Autoantibody measurement 
Indirect immunofluorescence (IIF) was performed on all samples. For the RBH SSc patients, 
ACA were determined by IIF, ATA by counter-immune electrophoresis (CIEP) and anti-RNA-
polymerase-III by INOVA ELISA. Samples negative for ACA, ATA and anti-RNA-polymerase-III 
were further assessed by radiolabelled protein immunoprecipitation (IPP). All RNHRD SSc 
sera and controls were screened by both IIF and IPP. 
 
Indirect immunofluorescence 
 IIF was performed on HEp-2 cells (Immunoconcepts, USA) using either fluorescein-labelled 
anti-Human IgG (Sigma, UK) (for patient samples) or fluorescein-labelled anti-rabbit IgG 
(Sigma, UK) (for the anti-eIF2Bβ control). Samples were screened at 1:40 and where anti-
eIF2B positive, titred by serial dilution. 
 
Counter Immune Electrophoresis  
CIEP was performed as described previously (10) using lyophilised rabbit thymus extract 
(Pel-Freez, USA) and bovine spleen extract in PBS (Sigma). 
 
Protein Immunoprecipitation (IPP) using [35S]-methionine 
10 µl sera was mixed with 2 mg protein-A-Sepharose beads (Sigma, UK) in IPP buffer (10 mM 
Tris-Cl pH 8.0, 500 mM NaCl, 0.1% v/v Igepal) for 30 min. Beads were washed in IPP buffer 
prior to the addition of 120 µl [35S]-methionine labelled K562 cell extract (prepared from 
15x106 cells/ml). Samples were mixed at 4°C for 2 hr. Beads were washed in IPP buffer and 
TBS buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl) before being resuspended in sample buffer 
(SB) (Sigma, UK). After heating, proteins were fractionated by 9% SDS PAGE and analysed by 
autoradiography. 
 
Immunodepletion Experiments 
Duplicate samples containing 10 mg protein-A-Sepharose beads and 40 µl case-E or normal 
control serum (NS) were mixed for 30 min. Beads were washed in IPP buffer, and 150 µl 
[35S]-methionine labelled K562 cell extract (prepared from 15x106 cells/ml) was added to 
one aliquot. Aliquots were mixed at 4°C for 2 hr, before the supernatants were transferred 
to the corresponding duplicate and mixed at 4°C for 2 hr. The supernatant was stored at -
80°C. IPP using 10 µl sera from anti-eIF2B positive patients and either 500 µl NS depleted or 
case-E depleted [35S]-methionine labelled cell extracts were completed as described for IPP 
using [35S]-methionine. 
 
Mass Spectrometry (MS) 
IPP was completed using 40 µl serum, 4 mg protein-A-Sepharose beads and 5 mM bis-
(sulphosuccinimidyl)-suberate (Perbio, UK). Beads were incubated in 4 ml K562 cell extract 
(prepared from 28x106 cells/ml) for a total of 4 hr at 4°C. Samples were resuspended in SB 
and heated. Proteins were fractionated by 10% SDS-PAGE and stained with Imperial Protein 
Stain (Perbio, UK). Bands were prepared for MALDI-TOF MS at the University of the West of 
England. Database matching using the ProteinLynx software required peptide coverage of 
over 20% with matching of the major theoretical and experimental peptide peaks. 
 
IPP-Blotting 
IPP was completed using either 40 µl sera (case-E, case-F, NS or serum containing known 
autoantibodies) or 20 µl polyclonal rabbit anti-eIF2BB antibody, 4 mg protein-A-Sepharose 
beads and 5 mM bis-(sulphosuccinimidyl)-suberate (Perbio, UK). Beads were incubated in 1 
ml K562 cell extract (prepared from 28x106 cells/ml) for a total of 2 hr at 4°C. Samples were 
resuspended in SB, heated and fractionated by 10% SDS-PAGE. Immunoprecipitates were 
transferred to nitrocellulose and probed with rabbit polyclonal anti-eIF2BB antibody (1:500 
dilution) for 90 min. Bands were detected using alkaline phosphatase conjugated goat anti-
rabbit IgG (1:25000 dilution) (Sigma, UK) and BCIP/NBT liquid substrate (Sigma, UK). 
 
Statistical Analysis 
Clinical associations were derived from 2×2 contingency tables. Probabilities were calculated 
using Fisher's exact test except where the 2×2 contingency tables included a ‘0’, in which 
case p-values were calculated by 1-sided Barnards Test. Where applicable, data were 
expressed as odds ratios with 95% confidence intervals. Data were analysed using ‘R’ 
software. 
 
Results 
Frequency of Known Autoantibody Specificities in SSc 
223 (58.8%) RBH SSc and 105 (62.1%) RNHRD SSc serum samples were positive for ACA, ATA 
or anti-RNA-polymerase-III. The respective frequencies are given in Table 1. The RBH cohort 
was enriched for patients suffering from ILD explaining the higher ratio of ATA to ACA 
compared to the RNHRD patients (RBH 2.7:1 vs RNHRD 0.4:1). Similarly, the association of 
ATA with dcSSc enriched the RBH cohort for dcSSc patients compared with the RNHRD 
patients (33.0% vs 17.2%). 
 
IPP on the RNHRD samples, and the RBH the samples negative for ACA, ATA and anti-RNA-
polymerase-III revealed a variety of autoantibodies recognised to occur in SSc or SSc-overlap 
including; anti-PM-Scl, anti-U1-RNP, anti-U3-RNP and anti-Ku. In addition, anti-tRNA 
synthetase antibodies were seen in six samples; four with anti-Jo-1 (anti-histidyl-tRNA 
synthetase) and two with anti-PL-12 (anti-alanyl-tRNA synthetase). Additional analysis of the 
RNHRD cohort confirmed the presence of anti-Th/To in seven patients (4.1%), one of which 
had co-existing anti-Ro60. Three of these anti-Th/To positive patients (42.9%) had ILD, 
which whilst not statistically significant, demonstrated a similar trend to described 
previously (11). 
 
Identification of a novel SSc autoantibody 
Seven SSc sera (four RBH [A-D] and three RNHRD [E-G] patients) had a distinct IPP pattern 
(approximately 30, 40 and 53 kDa bands), that did not correspond to any previously 
identified SSc autoantigen. With the exception of one patient (G), who had co-existing anti-
Ro60, this pattern was found to be mutually exclusive from other autoantibodies tested for 
by IIF or IPP. This pattern was not seen in immunoprecipitations using sera from disease or 
healthy control groups (p<0.001).  Overall the prevalence of this autoantibody in the entire 
cohort was 1.3% (assuming the RBH ACA, ATA and anti-RNA-polymerase-I/III positive 
samples were negative for eIF2B) or 1.8% in the RNHRD cohort, all of which were screened 
by IPP. 
 
Autoantigen identification 
Immunodepletion studies demonstrated that the IPP pattern seen with the seven cases was 
due to the precipitation of the same autoantigen. When cell extracts were pre-depleted 
with NS, novel antigens were still visible after IPP with each of the patient’s samples (Figure 
1A). However, after pre-depletion with case-E serum, and removal of the corresponding 
targets, the 30 and 40 kDa bands were absent, or greatly diminished, after subsequent IPP 
by case A-G serum (Figure 1A). These results strongly imply that all seven sera target the 
same protein complex.  
 
Identification of eIF2B as the Target Autoantigen 
IPP and SDS-PAGE demonstrated the presence of approximately 30 and 60 kDa bands using 
serum from case-E (data not shown). MALDI-TOF MS and Swiss Prot analysis of the peptide 
fingerprints corresponded to Eukaryotic Initiation Factor 2B, subunit β (eIF2BB) and subunit 
δ (eIF2BD) respectively. These results were consistent when repeated on two separate 
occasions. 
 
Confirmation of eIF2B as the Target Autoantigen 
IIF of HEp-2 cells using the positive cases resulted in a fine cytoplasmic speckled pattern for 
all cases, with titres between 1:160 to 1:2560 (Table 2). This same pattern was seen on IIF 
using commercial anti-eIF2Bβ serum (Supplementary Figure 1). Additional confirmation of 
the target autoantigen was established by IPP-Blot. IPP was completed using a commercial 
antibody to eIF2Bβ, case-E and case-F sera, NS and sera containing known autoantibodies. 
When the immunoprecipitates were transferred to nitrocellulose and probed with the anti-
eIF2Bβ antibody, bands were seen at the appropriate molecular weight with the eIF2Bβ, 
case-E and case-F immunoprecipitates. No bands were apparent with the NS or 
immunoprecipitates from patients with other known autoantibodies (Figure 1b). These 
results show that the novel precipitation pattern seen with SSc patients is due to 
autoantibodies directed against eIF2B. 
 
Clinical Features of Patients with anti-eIF2B Autoantibodies 
Clinical features of the seven patients with anti-EIF2B are given in Table 2. The presence of 
anti-eIF2B autoantibodies was associated with dcSSc compared to the anti-eIF2B negative 
SSc patients (85.7% (6 out of 7 patients) vs 31.1% (148 out of 476 patients), p<0.017 OR: 
13.30 [1.59-111.44]). Two patients had evidence of co-existing myositis and two of RA/SSc 
overlap. Six patients had documented ILD by HRCT that appeared typical of scleroderma 
lung. The seventh patient did not have an HRCT, but did have a reduced pulmonary transfer 
factor (TLco 74% predicted) and was believed to have some pulmonary involvement, 
however due to the uncertain ILD diagnosis this patient was excluded from statistical 
analysis. The association of anti-eIF2B and ILD was borderline significant across the entire 
cohort (100% (6 patients) vs 63.4% (343 from 541 patients), p=0.05), despite the increased 
ILD bias of the cohort due to the inclusion of the RBH patients. When analysing the 
association of anti-eIF2B and ILD against the more representative RNHRD cohort, ILD was 
found to be a strongly associated risk factor in the anti-eIF2B positive patients (100% (6 
patients) vs 25.9% (43 patients from 166) p<0.001). 
 
Discussion 
Here we report the identification of a novel autoantibody, anti-eIF2B, in seven SSc patients. 
Four patients formed part of a cohort of SSc patients assessed for ILD at a national unit, with 
the remaining patients attending a regional rheumatology centre. Anti-eIF2B autoantibodies 
are uncommon within the SSc cohort only being found in 1.3% of patients. However, whilst 
all of the RNHRD patients were screened for anti-eIF2B by IPP, the 223 RBH samples found 
positive for ATA, ACA or anti-RNA-polymerase-III were not screened by this method and not 
tested for anti-eIF2B. Whilst none of the RNHRD patients with anti-eIF2B had co-existing 
ATA, ACA or anti-RNA-polymerase-III autoantibodies, it is possible that some additional 
patients in the RBH cohort are positive for anti-eIF2B, making the frequency higher than 
described.  
 
The presence of anti-eIF2B corresponded with an increased risk of ILD, with six patients 
having definite ILD and the seventh having a reduced pulmonary transfer factor. 
Furthermore, six of the patients with anti-eIF2B had dcSSc. Over half of the anti-eIF2B 
positive patients had overlap features of either myositis or RA, although the autoantibody 
was not detected in any of the control cohorts, strongly inferring that the autoantibody is 
specific for SSc or SSc-overlap patients. 
Previous reports have shown that the prevalence of autoantibodies to nuclear autoantigens 
in SSc patients ranges from 85-99% (2), with similar frequencies found in both the RBH and 
RNHRD cohorts. Interestingly, none of the seven anti–eIF2B positive sera had a positive 
ANA, but all had a cytoplasmic speckle on IIF; consistent with the cytoplasmic location of 
eIF2B. It may therefore be useful to investigate ANA negative SSc patients for the presence 
of anti-eIF2B autoantibodies in the appropriate clinical context. 
Similarly to other cytoplasmic autoantigens, eIF2B is involved in protein translation. eIF2B is 
a multimeric protein consisting of 5 subunits that regulate a key step in protein synthesis 
(12). There have been reports of autoantibodies to other proteins in the eukaryotic protein 
initiation pathway, including anti-eIF3 in polymyositis (13) and anti-Agonaute/Su (eIF2C) in 
SLE (14). Interestingly, it has been demonstrated that Epstein-Barr virus expresses 
potentially immunogenic viral matches to all of the eIF2B subunits (15); and studies have 
demonstrated 58% of SSc patients to have abnormal antibodies to EBV (16). It is therefore 
possible that anti-eIF2B autoantibodies are formed in selected SSc patients due to EBV 
molecular mimicry. 
 
We report a new autoantibody, anti-eIF2B in 1-2% of SSc patients. This autoantibody is 
significantly associated with dcSSc and ILD, with a number of anti-eIF2B positive patients 
also having overlap features of myositis or RA. Sera from patients with anti-eIF2B 
autoantibodies are ANA negative, but have a cytoplasmic staining pattern by IIF, 
demonstrating anti-eIF2B to be the first SSc-specific cytoplasmic autoantibody. Further work 
is now required to understand why eIF2B is targeted by the immune system of these 
patients. 
 
Acknowledgements 
We thank P Owen and J Dunphy (Bath Institute for Rheumatic Diseases, UK) and Dr S 
Tansley (University of Bath) for their technical assistance.  
References 
1. Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). 
Rheumatic diseases clinics of North America. 2003;29(2):211-37. 
2. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. 
Autoimmunity reviews. 2013;12(3):340-54. 
3. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Current 
opinion in rheumatology. 2007;19(6):580-91. 
4. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA, Jr. A clinical and serologic 
comparison of African American and Caucasian patients with systemic sclerosis. Arthritis 
and rheumatism. 2012;64(9):2986-94. 
5. Domsic RT. Scleroderma: the role of serum autoantibodies in defining specific 
clinical phenotypes and organ system involvement. Current opinion in rheumatology. 
2014;26(6):646-52. 
6. Steen VD. The many faces of scleroderma. Rheumatic diseases clinics of North 
America. 2008;34(1):1-15; v. 
7. Masi AT. Classification of systemic sclerosis (scleroderma): relationship of cutaneous 
subgroups in early disease to outcome and serologic reactivity. The Journal of rheumatology. 
1988;15(6):894-8. 
8. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Jr., et al. 
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. The Journal of 
rheumatology. 1988;15(2):202-5. 
9. Aguila LA, Lopes MR, Pretti FZ, Sampaio-Barros PD, Carlos de Souza FH, Borba 
EF, et al. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory 
myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid 
arthritis. Clinical rheumatology. 2014;33(8):1093-8. 
10. Bernstein RM, Bunn CC, Hughes GR. Identification of antibodies to acidic antigens 
by counterimmunoelectrophoresis. Annals of the rheumatic diseases. 1982;41(5):554-5. 
11. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA, Jr. A comparison between 
anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited 
cutaneous involvement. Arthritis and rheumatism. 2003;48(1):203-9. 
12. Pavitt GD. eIF2B, a mediator of general and gene-specific translational control. 
Biochemical Society transactions. 2005;33(Pt 6):1487-92. 
13. Betteridge Z, Chinoy H, Vencovsky J, Cooper R, McHugh N. Identifaction of 
autoantibodies to a novel autoantigen protein complex (EIF3) in polymyositis patients. 
Rheumatology. 2011;50(Suppl 3):167. 
14. Satoh M, Chan JY, Ceribelli A, Vazquez del-Mercado M, Chan EK. Autoantibodies 
to Argonaute 2 (Su antigen). Advances in experimental medicine and biology. 2013;768:45-
59. 
15. Carter CJ. Epstein-Barr and other viral mimicry of autoantigens, myelin and vitamin 
D-related proteins and of EIF2B, the cause of vanishing white matter disease: massive 
mimicry of multiple sclerosis relevant proteins by the Synechococcus phage. 
Immunopharmacology and immunotoxicology. 2012;34(1):21-35. 
16. Fattal I, Shental N, Molad Y, Gabrielli A, Pokroy-Shapira E, Oren S, et al. Epstein-
Barr virus antibodies mark systemic lupus erythematosus and scleroderma patients negative 
for anti-DNA. Immunology. 2014;141(2):276-85. 
 
